Aurora Cannabis Stock (TSX: ACB) (NYSE: ACB) - Investor Dashboard


Aurora Cannabis
TSX: ACB
NYSE: ACB
Sector: Healthcare
Industry: Legal Cannabis
Country: Canada
Employees: >1400 as of 9/2018
Established: 2013
CEO: Terry Booth

Aurora Cannabis – Management Team


Terry Booth – CEO & Founder

terry-booth-aurora-cannabisTerry founded Aurora in 2013 when Health Canada announced the creation of the new MMPR program. Investing $2.5 million of his own capital in start-up funding Terry secured a 100 + acre parcel of land and began designing and building Aurora’s state of the art marijuana cultivation facility in Canada. To date he has served as President/CEO of 6 other highly successful companies including one that was awarded one of Canada’s top 50 fastest growing companies. Terry was instrumental in submitting and obtaining a Health Canada License to Produce Medical Marijuana for Aurora. Terry oversee’s the corporate strategy of the company including operations, sales, patient acquisition, doctor education programs, genetics development, regulatory affairs, facility expansion as well as the daily requirements of communicating with local and foreign capital markets and investors. Terry is a well-known community leader in his town of residence, Edmonton. There, he is known as a philanthropist and supporter of many worthy charitable causes such as early childhood development disabilities.


Steve Dobler, P. Eng – President

steve-dobler-peng-auroraSteve Dobler began his distinguished career in 1990 upon obtaining his Professional Engineering designation from the University of Alberta. Steve has held numerous executive positions in successful private and public Canadian companies over the past 25 years where he was responsible for the implementation of project management, strategies, and overseeing all facets of various operations. Currently serving as President for Alberta’s largest safety codes permitting company, his focus is on customers, innovation, and improved operational efficiencies which directly led to significant company growth. In 2011, the company was included in the top 50 of Canada’s fastest growing companies. Harvesting the initial idea of Aurora, Steve sought out the challenge shortly after identifying its potential. Personally investing $2 million of start up capital, Steve is largely responsible for the $8.6 million the company has raised to date.


Glen Ibbott – Chief Financial Officer

glenn-ibbott-aurora-cannabisGlen Ibbott is a seasoned senior healthcare executive with over 20 years’ experience providing financial leadership to various public entities, including management of Canadian and international capital market strategies, M&A, tax and finance, predominantly within the life sciences sector. An innovative, decisive, and insightful professional, he has excelled in delivering revenue and profitability growth, both domestically and internationally, strategy execution and shareholder value creation, including key contributions to numerous corporate transactions. Most recently, Mr. Ibbott was CFO at QLT Inc, a NASDAQ and TSX listed Biopharmaceutical Company and played a key role in QLT’s $500 million merger with Aegerion Pharmaceuticals to form Novelion Therapeutics. Prior to his time at QLT, Mr. Ibbott held various senior finance positions, including with globally operating companies such as Nordion, International Forest Products, Angiotech Pharmaceuticals, Aspreva Pharmaceuticals, and Inex Pharmaceuticals. Earlier in his career, he worked within the technology practice of KPMG. Mr. Ibbott completed MBAs at Cornell University and at Queen’s University, is a Canadian Chartered Professional Accountant (CPA, CA), as well as a US CPA, and holds a Bachelor’s of Business Administration from Simon Fraser University.


Cam Battley – Chief Corporate Officer

Mr. Battley has been with the company since 2016. In 2018, he was promoted to Chief Commercial Officer, a role in which he is responsible for creating and managing relationships in the cannabis industry. He has years of experience in the global biopharmaceutical industry, and he serves on the Cannabis Canada board of directors.


Allan Cleiren – Chief Operational Officer

Mr. Cleiren has nearly three decades of leadership experience in finance and operations management with both privately and publicly held companies in the life sciences, insurance, rail, construction, oil and gas service, and other sectors.. Most recently, Mr. Cleiren was COO with Jardine Lloyd Thompson Canada Inc. (JLT), one of the world’s leading providers of insurance, reinsurance and employee benefits related advice, brokerage and associated services. Prior to joining JLT, he served as Executive Vice President and formerly CFO for Universal Rail Systems Inc, and as Senior Vice President of Operations and CFO for Afexa Life Sciences. He is a member of the Board of Directors of Universal Rail Services Inc., Metalogic Inspection Services Inc., and is Chair of the Board for the Alberta Automobile Insurance Rate Board. Mr. Cleiren is a Chartered Professional Accountant (CPA, CA), holds a Bachelor of Commerce from the University of Alberta, and has a Diploma in Management Sciences from the Grant MacEwan College in Alberta. Mr. Cleiren also holds a ICD.D designation through the Institute of Corporate Directors.


Jason Dyck, Phd – Director and Head of Research Council

jason-dyck-phd-aurora-cannabisDr. Dyck is a Professor in the Department of Pediatrics and the Director of the Cardiovascular Research Centre at the University of Alberta. He is also the co-director of the Alberta HEART, which is a province-wide program aimed at understanding and treating diastolic heart failure. He co-founded a successful University of Alberta spin-off company, currently holds more than 100 patents and has numerous collaborations with large pharmaceutical companies. His accomplishments in academic research, drug discovery and product/technology commercialization have contributed to Dr. Dyck being recognized as one of Canada’s Top 40 under 40 (awarded by the Caldwell Partners in 2007), which is “presented to exceptional Canadians under the age of 40 who are outstanding leaders in their chosen fields and who are shaping our country’s future.”


Debra Wilson, PhD – Chief Human Resources Officer

Dr. Wilson joined Aurora Cannabis in 2017 as Vice President and Senior Vice President of Human Resources. In August 2018, she was promoted to Chief Human Resources Officer. Dr. Wilson completed her MBA at Royal Roads University and her PhD in industrial and organizational psychology at Capella University. Prior to joining Aurora, she held HR leadership positions at companies including Universal Rail Systems and Alberta Pensions Services Corporation.


Darryl Vleeming – Chief Information Officer

Aurora appointed Mr. Vleeming, previously Vice President of Information Systems and CIO of Capital Power Corporation, CIO in 2017. He was more than two decades of experience in senior IT leadership positions. Mr. Vleeming earned his Executive MBA from the University of Athabasca and his Computer Systems Technology Honors Diploma from the Northern Alberta Institute of Technology.


Neil Belot – Chief Business Development Officer

Mr. Belot, the former executive director of Cannabis Canada, was appointed Aurora’s Chief Brand Officer in 2015 and promoted to Chief Business Development Officer in 2017. He earned his MBA at Dalhousie University and Copenhagen Business School. He has years of experience in the cannabis industry, working under MMAR, MMPR, and ACMPR regulations.

Significant Insider Ownership


Terry Booth, CEO
10.06mm shares

Steve Dobler, President
19.35mm shares


Visit Aurora Cannabis
at www.auroramj.com.

New Cannabis Ventures in partnership with due diligence platform 420Investor, is the definitive source for fact-based, data-driven, financial information and relevant company news for qualified publicly traded cannabis companies. NCV extracts and parses only the most important content. Information is provided “as is” and solely for informational purposes, not for trading or advice. Aurora Cannabis is a client of NCV Media, LLC. Read our full disclaimer.